Brain health disorders including Alzheimer’s, dementia, depression, and stroke-related cognitive decline currently cost the global economy $5 trillion a year. By 2030, that figure is projected to reach $16 trillion. And yet, until recently, this crisis barely registered in the rooms where economic policy gets made.
That changed at Davos this January. On the sidelines of the World Economic Forum, conversations connected brain health not just to healthcare budgets but also to workforce productivity and to the competitive positioning of companies and nations in the age of AI. Much of it coalesced around a new report from the World Economic Forum and the McKinsey Health Institute. Three threads from those conversations deserve a much wider audience.
1. The AI Economy Runs on Healthy Brains
The paradox at the heart of the AI revolution: the more artificial intelligence automates routine work, the more valuable human intelligence and creativity become. 21st century jobs will demand higher-order thinking, creativity, and adaptive problem-solving. The age of AI is simultaneously the age of brain capital.
Dr. Harris Eyre, neuroscientist and co-author of the Davos report, puts it plainly: companies and nations that invest in brain health will have workforces capable of thriving in the AI transition. By 2050, the ratio of working-age adults to retirees will drop globally from roughly 8:1 to 4:1. We need every brain working at full capacity. Unhealthy brains caused by Alzheimer’s and mental health conditions don’t just steal individual futures, they diminish the capacity of current workers, turning many into caregivers. A company’s focus on the brain health and resilience of its workforce is not health philanthropy or just another HR issue. It is a strategic imperative for Boards and CEOs navigating the era of AI.
The Global Brain Capital Index, launched at Davos, maps cognitive health investment against economic productivity in terms finance ministers and development banks can act on. It offers a common language for translating a health crisis into economic policy and it is already shifting how governments frame their obligations to aging populations.
2. Women Are Both the Most Affected and the Most Powerful Force for Change
Almost two-thirds of people living with Alzheimer’s are women, who also provide more than 60 percent of unpaid dementia caregiving globally, sacrificing wages, career progression, and their own health. If you want to understand why the gender pay gap persists and why female workforce participation plateaus in midlife, dementia is part of the answer.
But there is another dimension rarely told alongside it. An estimated $84 trillion in assets will transfer between generations in the United States alone over the next two decades. Because women outlive men by several years, much of that wealth will move through female hands. McKinsey projects American women will control much of the Baby Boomers’ $30 trillion by 2030. Women are simultaneously the primary victims of Alzheimer’s, the primary caregivers, and the emerging primary holders of the private capital that could fund the next generation of research and prevention. Engaging them as economic decision-makers and impact investors is one of the most underleveraged opportunities in brain health.
3. The Global South Can Leapfrog, If We Build the Infrastructure Now
By 2050, India will see its over-60 population grow by 300 million or more and Africa alone will account for over 200 million dementia cases. 70 percent of all global cases will occur in low- and middle-income countries. But LMICs are not just the future epicenter of dementia burden; they are also home to the fastest-growing working-age populations on earth. A brain health crisis left unaddressed in these regions doesn’t stay there. It suppresses productivity, strains caregiving systems, and constrains the very economic growth that global supply chains, investment portfolios, and development strategies depend on. Investing in early detection and prevention infrastructure in the Global South is not charity. It is a hedge against the most predictable workforce disruption of the next half-century
Yet 90 percent of current genetic studies occur in just 10 percent of the world’s population, which means the treatments being developed today may not work for the communities facing the largest burden tomorrow. Countries in the Global South have a genuine chance to leapfrog the fragmented, reactive healthcare systems developed nations built in the 20th century, integrating early detection into primary care and building clinical trial capacity from the ground up. Lower-cost, non-therapeutic prevention solutions being developed in the Global South can also help the Global North address its own Alzheimer’s burden: ultimately, treatments that work for everyone require data from everyone.
Davos talked about brain health this year in a way it never has before. The harder work of broadening those conversations from health ministries to include finance ministries, CEOs, insurance and pension fund boardrooms, and corporate and national AI strategies is what comes next. The question is whether enough people inside boardrooms and national cabinet positions understand what is at stake.
